Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer
Xiaoshan Wang(Rosatom (Russia)), Ming Zeng(Jiangsu Province Hospital), Bangxian Tan(Affiliated Hospital of North Sichuan Medical College), Haixia Pan(University of Electronic Science and Technology of China), Hansong Bai(Sichuan Cancer Hospital), Xue Cheng(Wuhan University), Ruilian Yu(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital), Yan Guo(MACOM (United States)), Vivek Verma(Christ University), Xinbao Hao(Hainan Medical College Hospital), Gang Feng(University of Electronic Science and Technology of China), Kai Zhang(Second Affiliated Hospital of Jilin University), You Lü(Sichuan University), Hao Liu(Shihezi University), Simin Li(Leipzig University), Wei Tian(Wuxi No.2 People's Hospital), Xing Luo(University of Electronic Science and Technology of China), Fanxin Zeng(Dazhou Central Hospital), Ying Deng(Fudan University), Mingxiu Zhou(University of Electronic Science and Technology of China), Yingyi Liu(Union Hospital), Ke Xie(University of Electronic Science and Technology of China), Yifeng Bai(University of Electronic Science and Technology of China), Liang-Fu Han, Yuemei Sun(Affiliated Hospital of North Sichuan Medical College), Lan Yang(University of Electronic Science and Technology of China), Rui Ao(University of Electronic Science and Technology of China), Zi-Can Zhang(Affiliated Hospital of North Sichuan Medical College), Lin Jia(Mianyang Third People's Hospital), You‐Yu Wang(University of Electronic Science and Technology of China)
Cited by 267
Related Papers
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412
Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014
|Clinical Microbiology and Infection|2016|376
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
|Science Translational Medicine|2016|254